TY - JOUR
TI - Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer
AU - Pezaro, C.J.
AU - Omlin, A.
AU - Mastris, K.
AU - Attard, G.
AU - Beer, T.M.
AU - Chi, K.N.
AU - Chowdhury, S.
AU - Davis, I.D.
AU - Drake, C.G.
AU - de Bono, J.S.
AU - Efstathiou, E.
AU - Gravis, G.
AU - Higano, C.S.
AU - Hussain, M.
AU - James, N.
AU - Logothetis, C.J.
AU - Morgans, A.
AU - Parker, C.
AU - Ryan, C.J.
AU - Saad, F.
AU - Sartor, O.
AU - Small, E.J.
AU - Sternberg, C.N.
AU - Sweeney, C.J.
AU - Tannock, I.
AU - Tombal, B.
AU - Gillessen, S.
AU - ANZUP Consumer Advisory Panel
JO - Annals of Oncology
PY - 2017
VL - 28
TODO - 8
SP - 1692-1694
PB - Oxford University Press
SN - 0923-7534, 1569-8041
TODO - 10.1093/annonc/mdx312
TODO - abiraterone;  abiraterone acetate;  docetaxel;  enzalutamide;  testosterone, advanced cancer;  androgen deprivation therapy;  cancer survival;  castration resistant prostate cancer;  Editorial;  human;  measurement precision;  medical terminology;  metastatic prostate cancer;  overall survival;  practice guideline;  priority journal;  prostate cancer;  stigma;  castration resistant prostate cancer;  classification;  male;  nomenclature, Humans;  Male;  Prostatic Neoplasms, Castration-Resistant;  Terminology as Topic
TODO - null
ER -